Selank

Quick Facts

Introduction

Selank is a synthetic heptapeptide built from the endogenous immunomodulatory tetrapeptide tuftsin, extended for stability. It was developed in the same Russian neuropeptide research tradition as Semax, and the two are routinely studied side by side: where Semax is framed primarily around cognition and neuroprotection, Selank is framed primarily around anxiolytic and stress-resilience endpoints.

The conceptual interest in Selank is that a short, tuftsin-derived peptide appears to influence both neuroimmune signaling and classical neurotransmitter systems associated with anxiety — particularly GABAergic and serotonergic pathways — without the sedation or dependence liability that researchers associate with benzodiazepine-class compounds. Like Semax, it is studied predominantly through intranasal administration.

This profile covers what Selank is, the structural extension that gives it metabolic stability, its proposed neuroimmune and GABAergic mechanisms, the anxiolytic and cognitive research it appears in, and how it compares with related nootropic peptides such as Semax and the TREK-1-targeting PE-22-28. Related compounds are catalogued in the peptide database.

What is Selank?

Selank is based on tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain known for stimulating phagocytic and immunomodulatory activity. To this core it adds the C-terminal tripeptide Pro-Gly-Pro, giving the full sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP).

As with Semax, the Pro-Gly-Pro extension is the key design feature. Native tuftsin is rapidly degraded by serum and tissue peptidases, which limits its usefulness as a centrally acting research tool. The terminal prolines slow enzymatic cleavage substantially, extending the functional window long enough for the peptide to exert measurable behavioral and neuroimmune effects after intranasal delivery.

Molecular and structural characteristics

Structurally, Selank pairs the basic, arginine- and lysine-rich tuftsin core — which carries its immunomodulatory identity — with a proline-rich stabilizing tail. The result is a compact, highly water-soluble peptide whose charge profile reflects its basic residues and whose stability reflects the proline cap. This combination is what allows it to be studied as a centrally active compound despite tuftsin's intrinsic fragility.

Mechanism of action

Selank's anxiolytic profile is most often attributed to modulation of the GABAergic system. Preclinical work has associated Selank with changes in the expression and activity of GABA-related signaling, providing a proposed substrate for its calming, anti-anxiety effects that is distinct from direct benzodiazepine-receptor agonism. This distinction is the central reason researchers describe it as a non-sedating, non-dependence-forming anxiolytic candidate.

A second, well-documented axis is the serotonergic and enkephalinergic system. Selank has been reported to influence serotonin metabolism and, like Semax, to slow the degradation of endogenous enkephalins by inhibiting the peptidases that break them down. Prolonging enkephalin signaling is one proposed contributor to its effects on mood and stress reactivity.

Reflecting its tuftsin origin, Selank also retains neuroimmune activity. Research has associated it with shifts in the balance of pro- and anti-inflammatory cytokines, including interleukin expression, and with modulation of immune-cell function. Some studies additionally report increases in BDNF expression, linking the peptide's immune lineage to the neurotrophic themes shared across the nootropic-peptide class.

• Modulation of GABAergic neurotransmission (non-benzodiazepine).
• Effects on serotonin metabolism and mood-related signaling.
• Reported inhibition of enkephalin-degrading peptidases.
• Neuroimmune modulation of cytokine/interleukin balance.
• Reported increases in BDNF expression.

Anxiolytic and stress-resilience research

The endpoint most associated with Selank is anxiety reduction. In rodent models it has been studied in established anxiety paradigms, and small clinical studies in the Russian literature have examined it in the context of generalized anxiety and stress-related complaints, frequently emphasizing the absence of the sedation and withdrawal phenomena researchers associate with benzodiazepines. The GABAergic and serotonergic mechanisms above are the leading explanations offered for these observations.

Because the anxiolytic effect is framed as non-sedating, Selank is also studied for stress-related cognitive performance — the idea that reducing anxiety can indirectly support attention and learning under pressure. This places it in the same conceptual conversation as other nootropic peptides studied for focus and resilience, including Semax and the synaptogenesis-focused Dihexa.

Neuroimmune research

Because its core is tuftsin, Selank occupies a distinctive position among nootropic peptides: it is studied at the intersection of mood regulation and immune function. Research has associated it with normalization of cytokine profiles under stress and with modulation of the expression of genes tied to both immune and nervous-system function, suggesting that part of its behavioral effect may be mediated through neuroimmune crosstalk rather than neurotransmitter systems alone.

Comparison: Selank vs Semax vs PE-22-28

Selank is most often compared with Semax, its cognition-focused counterpart from the same research lineage, and with PE-22-28, a spadin-derived peptide studied for mood through a different molecular target (the TREK-1 potassium channel). All three are short peptides investigated for central nervous system effects, but they differ in mechanism and emphasis.

Researchers sometimes study Selank and Semax together because their proposed mechanisms — GABAergic/neuroimmune versus neurotrophic — are framed as complementary. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Selank is characterized by a short circulating half-life measured in minutes, even with the protective Pro-Gly-Pro extension. The terminal prolines slow degradation enough to permit central effects but do not produce a long systemic exposure. This is why the peptide is studied predominantly via the intranasal route, which is examined as a way to favor direct nose-to-brain transport and reduce reliance on systemic distribution.

As with Semax, an interpretive nuance is that Selank's degradation generates fragments — including Pro-Gly-Pro — that carry their own biological activity. The functional duration of effect can therefore outlast the parent peptide's measurable plasma concentration, so researchers treat simple half-life figures as an incomplete description of its activity.

Reconstitution and handling considerations

Lyophilized Selank is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The reconstituted solution should be clear and colorless; cloudiness or particulates indicate it should be discarded. Because the peptide is frequently prepared for intranasal research use, concentrations are chosen so that small, reproducible volumes deliver the intended amount.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear and colorless before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized Selank is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled. Nasal preparations in particular benefit from cold storage and protection from light.

Research limitations

Selank has a substantial research history, but much of its evidence base comes from preclinical models and from clinical research conducted within a single national research tradition, with limited large-scale independent replication outside it. Reported effects are dose-, route-, and design-dependent, and the relationship between its short plasma half-life and its longer functional effects remains an active research question. It is described here strictly for research reference.

• Much evidence is preclinical or from a single research tradition.
• Independent large-scale replication is limited.
• Reported effects are dose-, route-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology. 2003.
2. Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology. 2016.Source
3. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii. 2008.